London Daily

Focus on the big picture.
Thursday, Sep 11, 2025

Oxford/AstraZeneca vaccine results face growing scrutiny

Oxford/AstraZeneca vaccine results face growing scrutiny

Share price drops as critics question claim vaccine could protect up to 90% of people
The Oxford University/AstraZeneca vaccine will undergo a new global trial as critics questioned the claim that it could protect up to 90% of people against coronavirus.

On Thursday Sir John Bell, Oxford’s regius professor of medicine and the UK government’s life sciences adviser, dismissed suggestions the previous trial had not been properly set up or reported. “We weren’t cooking this up as we went along,” he said, adding that he hoped the full, peer-reviewed data would be published in the Lancet medical journal at the weekend.

In spite of the public excitement generated by the announcement that a third vaccine had been successful – with particular promise for developing countries as it is relatively cheap and can be stored at fridge temperature – AstraZeneca’s share price dropped.

One analyst in the US wrote in an investor note that “we believe that this product will never be licensed in the US” and alleged the company had tried to “embellish” the results.

It comes after the headline figure for the vaccine’s overall efficacy was put at 70% – as announced by the company on Monday and discussed in a press briefing by the Oxford researchers. But a sub-set of fewer than 3,000 people in the UK was given a lower dose regime – originally by accident – where the efficacy rose to 90%. In most trial volunteers in Brazil and the UK, it was 62%.

Sir Mene Pangalos, AstraZeneca’s head of biopharmaceuticals R&D, has confirmed that the low-dose trial included nobody over the age of 55. This led to concerns that younger age may have been a factor – particularly relevant given that vulnerable elderly people are most at risk from Covid-19.

Researchers had no explanation for the 90% result in people given a half dose followed by a whole dose of the vaccine, instead of two whole doses in other arms of the trial.

On Thursday AstraZeneca said it would undertake a new global trial using the lower-dose regimen. The timeline for regulatory approval and rollout of the vaccine in the UK and Europe should not be affected.

Critics have also claimed the trials did not include enough ethnic diversity, gender and age balance to satisfy the US regulator, the Food and Drug Administration.

Defending the vaccine trials, Bell told a symposium run by the Faculty of Pharmaceutical Medicine: “[The] MHRA [Medicines and Healthcare Products Regulatory Authority] knew perfectly well what we were doing. They approved all the protocols.”

It had been widely accepted before any of the vaccine trials reported results that 60% efficacy would be enough for a licence and would be useful, he said. “We are well in excess of that. I can’t imagine any reason why regulators won’t accept that.”

America had not yet seen the full data, he said, which he hoped would be published in the Lancet at the weekend. “I think when they see the data, it will be a great deal easier to have these conversations.”

Scientists at Oxford and the company admitted they were surprised by the finding that a lower dosing regime got better results. Pangalos called it serendipity.

“It could be that by giving a small amount of the vaccine to start with and following up with a big amount, that’s a better way of kicking the immune system into action and giving us the strongest immune response and the most effective immune response,” said Prof Sarah Gilbert, who led the vaccine research at Oxford.

AstraZeneca’s CEO told Bloomberg it would begin an international trial using the lower-dose regimen, while previously it had been expected merely to add an arm to the existing trial in the US.

The move will be seen as a bid to satisfy the FDA and compete, if they do win a licence in the US, with Pfizer and Moderna which have both published data suggesting 95% efficacy.

“Now that we’ve found what looks like a better efficacy [in the half dose/full dose regime], we have to validate this, so we need to do an additional study,” CEO Pascal Soriot said on Thursday. The study would probably be global “but this one could be faster because we know the efficacy is high so we need a smaller number of patients”.

Peter Openshaw, professor of experimental medicine at Imperial College London, said more data would need to be collected if the low-dose arm of the trial included only under-55s.

“If this is true, it may mean we don’t have any information about this regimen in older adults,” he said. “We have to wait for the full data and to see how the regulators view the results of the phase 3 trials. The US and European regulators might possibly take a different view. All we have to go on is a limited data release.”

It was possible, he said, that the protection from the Oxford/AstraZeneca vaccine might be less than that from the Pfizer/BioNTech and Moderna vaccines, which were developed with a different technology based on RNA, “but we need to wait and see”.

Paul Hunter, professor in medicine at the University of East Anglia and an adviser on methodology to the World Health Organization, said he was always wary of sub-group analyses in trials.

“Most of the time when you get these incredibly good results in a sub-group analysis, you have to be incredibly careful about believing them,” he told the Guardian. There could be something about the smaller group that was not true of the larger group.

He was also worried by the suggestion the sub-group had nobody over 55. “I’m not saying this isn’t going to be a fantastic vaccine at the end of the day, but we need a lot better understanding of the data,” he said.

An AstraZeneca spokesperson said an independent data safety monitoring board ensures the safety and quality of the trials. “The studies were conducted to the highest standards,” it said in a statement. “More data will continue to accumulate and additional analysis will be conducted refining the efficacy reading and establishing the duration of protection.”
Newsletter

Related Articles

0:00
0:00
Close
ChatGPT CEO signals policy to alert authorities over suicidal youth after teen’s death
The British legal mafia hit back: Banksy mural of judge beating protester is scrubbed from London court
Surpassing Musk: Larry Ellison becomes the richest man in the world
Embarrassment for Starmer: He fired the ambassador photographed on Epstein’s 'pedophile island'
Manhunt after 'skilled sniper' shot Charlie Kirk. Footage: Suspect running on rooftop during panic
Effective Protest Results: Nepal’s Prime Minister Resigns as Youth-Led Unrest Shakes the Nation
Qatari prime minister says Netanyahu ‘killed any hope’ for Israeli hostages
King Charles and Prince Harry Share First In-Person Moment in 19 Months
Starmer Establishes Economic ‘Budget Board’ to Centralise Policy and Rebuild Business Trust
France Erupts in Mass ‘Block Everything’ Protests on New PM’s First Day
Poland Shoots Down Russian Drones in Airspace Violation During Ukraine Attack
Brazilian police say ex-President Bolsonaro had planned to flee to Argentina seeking asylum
Trinidad Leader Applauds U.S. Naval Strike and Advocates Forceful Action Against Traffickers
Kim Jong Un Oversees Final Test of New High-Thrust Solid-Fuel Rocket Engine
Apple Introduces Ultra-Thin iPhone Air, Enhanced 17 Series and New Health-Focused Wearables
Macron Appoints Sébastien Lecornu as Prime Minister Amid Budget Crisis and Political Turmoil
Supreme Court temporarily allows Trump to pause billions in foreign aid
Charlie Sheen says his father, Martin Sheen, turned him in to the police: 'The greatest betrayal possible'
Vatican hosts first Catholic LGBTQ pilgrimage
Apple Unveils iPhone 17 Series, iPhone Air, Apple Watch 11 and More at 'Awe Dropping' Event
Pig Heads Left Outside Multiple Paris Mosques in Outrage-Inducing Acts
Nvidia’s ‘Wow’ Factor Is Fading. The AI chip giant used to beat Wall Street expectations for earnings by a substantial margin. That trajectory is coming down to earth.
France joins Eurozone’s ‘periphery’ as turmoil deepens, say investors
On the Anniversary of Queen Elizabeth’s Death: Prince Harry Returns to Britain
France Faces New Political Crisis, again, as Prime Minister Bayrou Pushed Out
Murdoch Family Finalises $3.3 Billion Succession Pact, Ensuring Eldest Son’s Leadership
Big Oil Slashes Jobs and Investments Amid Prolonged Low Crude Prices
Court Staff Cover Up Banksy Image of Judge Beating a Protester
Social Media Access Curtailed in Turkey After CHP Calls for Rallies Following Police Blockade of Istanbul Headquarters
Nayib Bukele Points Out Belgian Hypocrisy as Brussels Considers Sending Army into the Streets
Elon Musk Poised to Become First Trillionaire Under Ambitious Tesla Pay Plan
France, at an Impasse, Heads Toward Another Government Collapse
Burning the Minister’s House Helped Protesters to Win Justice: Prabowo Fires Finance Minister in Wake of Indonesia Protests
Brazil Braces for Fallout from Bolsonaro Trial by corrupted judge
The Country That Got Too Rich? Public Spending Dominates Norway Election
Nearly 40 Years Later: Nike Changes the Legendary Slogan Just Do It
Generations Born After 1939 Unlikely to Reach Age One Hundred, New Study Finds
End to a four-year manhunt in New Zealand: the father who abducted his children to the forests was killed, the three siblings were found
Germany Suspends Debt Rules, Funnels €500 Billion Toward Military and Proxy War Strategy
EU Prepares for War
BMW Eyes Growth in China with New All‑Electric Neue Klasse Lineup
Trump Threatens Retaliatory Tariffs After EU Imposes €2.95 Billion Fine on Google
Tesla Board Proposes Unprecedented One-Trillion-Dollar Performance Package for Elon Musk
US Justice Department Launches Criminal Mortgage-Fraud Probe into Federal Reserve Governor Lisa Cook
Escalating Drug Trafficking and Violence in Latin America: A Growing Crisis
US and Taiwanese Defence Officials Held Secret Talks in Alaska
Report: Secret SEAL Team 6 Mission in North Korea Ordered by Trump in 2019 Ended in Failure
Gold Could Reach Nearly $5,000 if Fed Independence Is Undermined, Goldman Sachs Warns
Uruguay, Colombia and Paraguay Secure Places at 2026 World Cup
Florida Murder Case: The Adelson Family, the Killing of Dan Markel, and the Trial of Donna Adelson
×